Research overview
What is Cerebrolysin?
Cerebrolysin is made by breaking down porcine brain proteins into a mixture of low-molecular-weight peptides and amino acids. Its composition and manufacturing context are integral to the studied product. A research product bearing the same name is not automatically comparable with the formulations used in trials.
What has research examined?
A large randomized, placebo-controlled acute ischemic stroke trial enrolled 1,070 participants and did not find a statistically significant difference on its confirmatory combined primary endpoint. A small randomized pilot involving 32 people with mild traumatic brain injury reported improvements on selected cognitive measures, but the size and endpoint breadth limit generalization. A Cochrane review of acute ischemic stroke trials found no probable benefit for preventing all-cause death and reported a possible increase in nonfatal serious adverse events. The studies examine different neurological situations and cannot be collapsed into a single claim of neuroprotection.
The clinical evidence is heterogeneous, with a negative large stroke trial and small exploratory results elsewhere. The review’s adverse-event signal and product-specific formulation further limit interpretation. This page does not recommend use or validate the identity or quality of any seller’s mixture.
Research references
- Cerebrolysin in patients with acute ischemic stroke in Asia: a double-blind, placebo-controlled randomized trialStroke
- Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: randomized pilot studyBritish Journal of Neurosurgery
- Cerebrolysin for acute ischaemic strokeCochrane Database of Systematic Reviews
Calculation boundary
Cerebrolysin contains multiple peptides and amino acids rather than one defined peptide with a single mg-to-molecule relationship. A generic vial-mass and U-100 syringe calculator would imply equivalence across mixtures and formulations that the available evidence does not establish.